IN8BIO, INC. — Director's Dealing 2024

Oct 8, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IN8BIO, INC. (INAB)
CIK: 0001740279
Period of Report: 2024-10-04

Reporting Person: Rochlin Kate (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-10-04	Common Stock	A	25316	—	Acquired	42874	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-10-04	Series A Warrants (right to buy)	$1.25	D	12295	Disposed	2025-06-13	Common Stock (12295)	Direct
2024-10-04	Series A Warrants (right to buy)	$0.45	A	12295	Acquired	2025-10-04	Common Stock (12295)	Direct
2024-10-04	Series C Warrants (right to buy)	$0.27	A	25316	Acquired	2027-10-04	Common Stock (25316)	Direct

Footnotes

F1: The reported securities are included within 25,316 Issuer Units purchased by the Reporting Person for $0.395 per Unit. Each Unit consists of one share of common stock and one Series C warrant representing the right to purchase 25,316 shares of common stock.

F2: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.25 and expiration date of June 13, 2025. The exercise price was reduced to $0.45 and the warrant expiration date was extended to October 4, 2025.

F3: Fully vested and exercisable.

F4: The reported securities are included within 12,295 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 20,492 shares of common stock.